lunes, 29 de enero de 2018

Recent Device Approval: Implantable System for Remodulin



FDA has recently approved the Implantable System for Remodulin to be marketed. This is an infusion system that is fully implanted into a patient to deliver Remodulin through a patient's veins. Remodulin (or Treprostinil) is a medication used to treat pulmonary arterial hypertension (high blood pressure in the arteries that go from the heart to the lungs).

No hay comentarios:

Publicar un comentario